Guggenheim Capital LLC lowered its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 13.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 261,433 shares of the biotechnology company’s stock after selling 40,688 shares during the period. Guggenheim Capital LLC’s holdings in Exelixis were worth $3,898,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC bought a new position in Exelixis during the third quarter valued at approximately $107,000. Geduld E E acquired a new position in shares of Exelixis during the third quarter worth approximately $128,000. Commerzbank Aktiengesellschaft FI acquired a new position in shares of Exelixis during the fourth quarter worth approximately $169,000. Fox Run Management L.L.C. increased its position in shares of Exelixis by 12.5% in the third quarter. Fox Run Management L.L.C. now owns 11,700 shares of the biotechnology company’s stock worth $150,000 after buying an additional 1,300 shares during the last quarter. Finally, National Planning Corp acquired a new position in shares of Exelixis during the fourth quarter worth approximately $255,000. 78.40% of the stock is owned by institutional investors and hedge funds.
Shares of Exelixis, Inc. (NASDAQ:EXEL) opened at 22.04 on Tuesday. The stock’s 50 day moving average is $21.49 and its 200-day moving average is $16.36. The stock’s market cap is $6.41 billion. Exelixis, Inc. has a 1-year low of $3.64 and a 1-year high of $23.49.
Exelixis (NASDAQ:EXEL) last released its earnings results on Monday, February 27th. The biotechnology company reported $0.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.13. The firm earned $77.58 million during the quarter, compared to analyst estimates of $64.88 million. During the same quarter last year, the business posted ($0.19) EPS. The firm’s revenue was up 680.7% on a year-over-year basis. On average, analysts predict that Exelixis, Inc. will post $0.05 EPS for the current fiscal year.
var userip;Your IP Address: document.write(userip);
A number of analysts recently weighed in on the stock. Zacks Investment Research raised shares of Exelixis from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a research report on Monday, February 6th. Cowen and Company reaffirmed an “outperform” rating on shares of Exelixis in a research report on Tuesday, January 24th. CIBC initiated coverage on shares of Exelixis in a research report on Thursday, March 16th. They set a “market perform” rating on the stock. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Saturday, January 28th. Finally, Stifel Nicolaus downgraded shares of Exelixis from a “buy” rating to a “hold” rating and set a $22.00 price objective on the stock. in a research note on Tuesday, February 28th. They noted that the move was a valuation call. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $16.76.
In other Exelixis news, Director Vincent T. Marchesi sold 40,000 shares of the firm’s stock in a transaction dated Friday, March 10th. The shares were sold at an average price of $21.98, for a total transaction of $879,200.00. Following the completion of the transaction, the director now directly owns 160,070 shares in the company, valued at approximately $3,518,338.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Peter Lamb sold 70,000 shares of the firm’s stock in a transaction dated Tuesday, January 3rd. The shares were sold at an average price of $14.65, for a total transaction of $1,025,500.00. The disclosure for this sale can be found here. Insiders sold a total of 407,250 shares of company stock valued at $8,635,613 in the last quarter. Insiders own 5.90% of the company’s stock.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.